

## Zamerovimab

## Chemical Properties

CAS No. : 2419087-87-7

Formula:

Molecular Weight:

Storage: -20°C for 1 year  
Actual storage temperature shall be subject to the COA.

## Biological Description

Description	Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1].
Targets(IC50)	Others
In vitro	Zamerovimab (CTB011; SYN023) at concentrations ranging from 0.001 to 100 µg/mL for 4 hours induces dose-dependent cytotoxicity in BSR cells infected with CVS, facilitating viral clearance. This cytotoxic effect is also shown to correlate with the cell specificity for expressing the G protein, which are targeted by CTB011 [1].
In vivo	Zamerovimab (CTB011; SYN023), administered via intramuscular injection into the right gastrocnemius at doses ranging from 0.03 to 1.0 mg/kg for a single dose on day 35, was shown to increase the survival rate of Syrian hamsters infected with the rabies virus RABV BD06 in a dose-dependent manner. At doses of 0.03, 0.1, 0.3, and 1.0 mg/kg, the survival rates were 58%, 83%, 100%, and 100%, respectively [1].

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481